摘要
目的:探讨雷公藤多苷(Tripterygium)联合rhIL-11治疗免疫性血小板减少症的疗效。方法:选取75例ITP患者并分为2组:实验组为雷公藤多苷+rhIL-11治疗组,共40例,接受雷公藤多苷1 mg/(kg·d)口服+重组人白介素-11 1600万单位,每天一次皮下注射;对照组为糖皮质激素治疗组,共35例,接受强的松1 mg/(kg·d)口服。治疗2个月,监测两组治疗前后血小板计数,评估疗效;应用流式细胞仪测定治疗前后T细胞亚群。结果:实验组总有效率77.5%,对照组总有效率82.9%,两组无统计学差异(P>0.05);实验组血小板上升至>30×109/L时间为13.06±6.10 d,对照组为9.76±5.71 d(P<0.05)。实验组CD4+T细胞比例治疗前为21.03%,治疗后为34.49%(P<0.01);治疗前CD8+T细胞比例为26.35%,治疗后降为20.18%(P<0.01)。对照组CD4+T细胞比例治疗前为22.30%,治疗后为25.11%(P<0.05);治疗前CD8+T细胞比例为27.24%,治疗后降为21.35%(P<0.01)。结论:雷公藤多苷纠正T淋巴细胞紊乱,雷公藤多苷联合rhIL-11治疗ITP具有起效时间短、疗效持久等特点,达到与糖皮质激素相当的疗效,且副作用少、费用低、患者耐受性好,可作为ITP患者的重要治疗方法。
Objective: To study the therapeutic efficacy of multigly-cosidorum Tripterygium combined with rhIL-11 for treating patients with immune thrombocytopenia( ITP). Methods: A total of 75 patients with ITP were divided into 2group: experimental group and control group. The experimental group included 40 patients who had been treated with multigly-cosidorum Tripterygium combined with rhIL-11. Multiglycosidorum Tripterygium was given at a dose of 1mg /kg·d for 2 months and rhIL-11 was injected at a dose of 16, 000, 000 units per day. Control group included 35 patients who had been treated with prednisone at a dose of 1 mg /kg·d. Platelet counts were performed every day before platelet counts > 30 × 109 /L. Peripheral blood T cells were collected before and after treated for 2 months. The ratios of CD4 +,CD8 + T cells in peripheral blood T cells were analyzed by flow cytometry. Results: Totally effective rate in experimental group was 77. 5%. Totally effective rate in control group was 82. 9%. Totally effective rate showed no statistical difference between these two groups( P > 0. 05). The average time of platelet count 30 × 109 /L in experimental and control groups were 13. 06 ± 6. 10 days and 9. 76 ± 5. 71 days respectively; in experimental group,the ratio of CD4 +T cells in peripheral blood was 21. 03% before treatment,then rised to 34. 49% after treatment for 2 months( P < 0. 01);The ratio of CD8 + T cells in peripheral blood was 26. 35% before treatment,then decreased to 20. 18%( P < 0. 01). In control group,the ratio of CD4 + T cells was 22. 30% before treatment,then rised to 25. 11% after treatment for 2months( P < 0. 05); The ratio of CD8 + T cells in peripheral blood was 27. 24% before treatment,then decreased to21. 35%( P < 0. 01). Conclusion: Multigly-cosidorum tripterygium can correct disorder of T lymphocytes,the combination of multigly-cosidorum triptergium and rhIL-11 can accelerate therapeutic efficacy for treating ITP and with less adverse reaction,so this combination may be effective and safe for treating patients with ITP.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2015年第5期1400-1403,共4页
Journal of Experimental Hematology
基金
镇江市科技支撑计划(社会发展)(FZ2011045)
江苏大学临床医学专项基金(JDLCZX003)
